What is more natural than cannabis?

Teva's big move

Teva Israel signed an exclusive agreement with the World Cannabis Amendment to purchase medical cannabis oils, about 3 weeks before the Ministry of Health committee to exclude the CBD from the Drug Ordinance is supposed to submit its recommendations.

Recently, the entry of pharmaceutical companies into the field has been evident, perhaps also in anticipation of widespread legalization in the United States

Roast Greenberg

26/12/2021

Sunday, 26 December 2021, 12:43 Updated: 12:57

• Share on Facebook

• Share on WhatsApp

• Share on Twitter

• Share on Email

• Share on general

• Comments

  Comments

Pharma giants expect federal legalization in the US? About two weeks after Pfizer announced its intention to acquire the CBD (non-psychoactive ingredient in the cannabis or cannabis plant - HEMP) Arena Pharmaceuticals for $ 6.7 billion, it turns out that Israeli Teva also wants an ambition in the field.

Teva announced , together with medical marijuana in public tikkun olam, an exclusive agreement for cooperation for a decade. Under the agreement, Teva will acquire a correction of world-finished products and will market and distribute them in Israel, Gaza, and the Palestinian Authority. and then possibly Ukraine and other countries.

This is an aromatherapy medical cannabis produced varieties society Metatron, which is rich in CBD and helps treat mainly epilepsy and autism, and 'Venus', which is rich in THC (the psychoactive ingredient in the cannabis plant) and helps treat pain and sleep.

More on Walla!

What is important to know in the event of an accident, and in a car insurance claim

Walla!

A vehicle in partnership with the Phoenix

Tikun Olam-Kanbit, selected by Teva after examining several factors (Photo: Chen Galili)

Will the US administration encourage legalization?

The companies have not reported any purchase or sales commitment, but it is known that the latter will be determined according to market demand, alongside the nature of Teva's success in sales. However, the assumption of cannabis agents is that Teva has not entered into an agreement with Tikun Olam exclusively for the benefit of sales whose height does not match the other products sold by it.

In this context, it should be noted that the acquisition of Arena by Pfizer was, according to the latter, intended to complete the cycle of drug treatment offered by Pfizer for immuno-inflammatory diseases. Mike Gladstone, president of the Department of Inflammation and Immunology at Pfizer, said at the time of the acquisition that Arena, which develops a CBD drug for intestinal disease, complements the company’s capabilities and expertise in the field.

Sources in the pharma world estimate that Pfizer's entry into the field indicates that the pharma companies' assessment is that the White House is on its way to approve legalization or federal decalification, which will allow the major pharma companies to enter into cannabis activities.

Production of cannabis oils at the Cannabis World Repair Factory.

Is it estimated that there will be federal legalization in the United States? (Photo: Chen Galili)

At the moment, the only activity they can engage in is CBD activity, which was exempted from the U.S. Drug Ordinance by the Trump administration through the Pharm Bill.

It is possible that Teva is preparing for the decision of the CBD Exclusion Committee from the Israeli Drug Ordinance, which is expected to submit its recommendations by January 15, 2022.

It should also be noted that so far Teva has operated indirectly in the cannabis field, through marketing and distribution agreements - SLA, with a number of Israeli medical cannabis companies, including the Saiki cannabis inhaler company.

In addition, the investment house of Teva and Philippe - Sanara Ventures, invested about $ 250,000 during 2019 in Veoli, which also develops a cannabis inhaler.

At this time, no cannabis inhaler is known to be taking the Israeli market by storm.

Avinoam Sapir, CEO of Tikkun Olam-Kanbit (Photo: Reuven Kapuchinsky)

"One of the most important agreements made in the industry in recent years"

Yossi Ofek, CEO of Teva Israel

, served as CEO of the company's Pharma, while

, served as CEO of Teva Israel before him.

Ofek said that "the field of medical cannabis is developing and professionalizing in Israel and is more open to it in Israel and around the world.

Today it is clear to many in the pharma industry and the medical community that the use of oils extracted from certain cannabis strains may provide additional treatment options."

Sapir added that "the fact that Teva made a decision to enter into an exclusive agreement with us for a decade, with the possibility of an extension of another 9 years by 3 beats, indicates the confidence it is acquiring in repairing the world."

In my opinion, this is one of the most important agreements made in the industry in recent years in Israel, and which will position the World-Cannabis Amendment, alongside Teva Israel, as a leading player in the field of medical cannabis, which is only developing both in Israel and abroad. "

• Of money

• news

Tags

• Medical Cannabis

• Tikkun Olam

• nature

• Cannabis